IMCIVREE (setmelanotide)
POMC deficiency obesity
Key Facts
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileAbout Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileAbout Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profile